The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy

Jonsson, Maria Karolina; Hensvold, Aase Haj; Hansson, Monika; Aga, Anna-Birgitte; Sexton, Joseph; Mathsson-Alm, Linda; Cornillet, Martin; Serre, Guy; Lillegraven, Siri; Fevang, Bjørg-Tilde Svanes; Catrina, Anca Irinel; Haavardsholm, Espen Andre

doi:10.1186/s13075-018-1635-7

Table 2 Baseline disease characteristics (median values) in anti-CCP and ACPA reactivity-positive versus reactivity-negative patients

From: The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy

		ESR		CRP		DAS		SJC44		RAI		US GS		US PD		vdHSS E		vdHSS JSN		vdHSS T
			p		p		p		p		p		p		p		p		p		p
Anti-CCP	+ (82%)	21	0.10	7	0.20	3.24	< 0.01	8	< 0.01	7	0.17	16	< 0.01	6	< 0.01	3	0.72	1	0.10	4	0.37
Anti-CCP	- (18%)	13	0.10	7	0.20	4.09	< 0.01	18	< 0.01	8	0.17	33	< 0.01	14	< 0.01	3	0.72	1.5	0.10	4.5	0.37
Fibβ 60–74	+ (75%)	20	0.63	7	0.04	3.28	0.02	7	< 0.01	7	0.65	17	< 0.01	6	< 0.01	3	0.97	1	0.71	4.5	0.73
Fibβ 60–74	- (25%)	19	0.63	10	0.04	3.87	0.02	14	< 0.01	7	0.65	28	< 0.01	11	< 0.01	3	0.97	0.5	0.71	3.5	0.73
Vim 60–75	+ (73%)	18	0.95	7	0.54	3.29	0.05	8	< 0.01	6	0.83	17	< 0.01	6	0.02	3	0.96	1	0.26	4.5	0.95
Vim 60–75	- (27%)	21	0.95	7	0.54	3.77	0.05	14	< 0.01	7	0.83	23	< 0.01	9	0.02	3	0.96	1	0.26	4	0.95
H4 31–50	+ (67%)	21	0.39	8	0.65	3.27	0.01	8	< 0.01	6	0.03	17	0.01	6	0.01	3	0.88	1	0.94	4.5	0.70
H4 31–50	- (33%)	17	0.39	7	0.65	3.84	0.01	13	< 0.01	10	0.03	21	0.01	9	0.01	3	0.88	0.75	0.94	3.25	0.70
CEP-1	+ (65%)	21	0.13	8	0.93	3.32	0.35	9	0.06	7	0.47	17	0.03	6	0.12	3	0.76	1	0.46	4.5	0.54
CEP-1	- (35%)	17	0.13	6	0.93	3.36	0.35	11	0.06	7	0.47	21	0.03	7	0.12	3	0.76	0.5	0.46	3.5	0.54
Fil 307–324	+ (63%)	21	0.15	8	0.70	3.29	0.06	7	< 0.01	7	0.54	17	0.01	6	< 0.01	3	0.94	1	0.98	4	0.91
Fil 307–324	- (37%)	17	0.15	7	0.70	3.64	0.06	13	< 0.01	7	0.54	21	0.01	9	< 0.01	3	0.94	1	0.98	4	0.91
Fibα 573	+ (57%)	22	0.13	8	0.85	3.27	0.03	7	< 0.01	6	0.14	17	0.05	6	0.12	3	0.61	1	0.23	4.5	0.37
Fibα 573	- (43%)	16	0.13	7	0.85	3.42	0.03	12	< 0.01	8	0.14	21	0.05	8	0.12	3	0.61	0.5	0.23	4	0.37
Fibβ 36–52	+ (54%)	21	0.08	8	0.78	3.26	0.05	8	< 0.01	6	0.06	17	0.06	6	0.03	3	0.58	1	0.05	4.5	0.19
Fibβ 36–52	- (46%)	17	0.08	7	0.78	3.63	0.05	11	< 0.01	8	0.06	19	0.06	8	0.03	3	0.58	0.5	0.05	3.5	0.19
H3 1–30	+ (49%)	18	0.97	7	0.40	3.29	0.48	8	0.09	6	1.00	17	0.04	6	0.09	3	0.62	0.5	0.04	4	0.16
H3 1–30	- (51%)	20	0.97	7	0.40	3.37	0.48	10	0.09	7	1.00	19	0.04	7	0.09	3	0.62	1	0.04	4.5	0.16
H4 14–34	+ (48%)	21	0.13	8	0.74	3.27	0.28	7	< 0.01	7	0.77	17	0.30	7	0.86	3	0.39	1	0.30	4	0.28
H4 14–34	- (52%)	18	0.13	7	0.74	3.45	0.28	11	< 0.01	7	0.77	20	0.30	6	0.86	3	0.39	1	0.30	4.5	0.28
H3 21–44	+ (44%)	22	0.09	9	0.21	3.31	0.69	9	0.07	7	0.84	17	0.28	6	0.41	3	0.68	0.5	0.14	4	0.32
H3 21–44	- (56%)	18	0.09	6	0.21	3.36	0.69	10	0.07	7	0.84	19	0.28	7	0.41	3	0.68	1	0.14	4.5	0.32
Fibα 621–635	+ (43%)	22	0.36	8	0.84	3.29	0.09	7	< 0.01	7	0.54	16	0.02	6	0.07	2.5	0.46	0.5	0.30	4	0.34
Fibα 621–635	- (57%)	18	0.36	7	0.84	3.37	0.09	12	< 0.01	7	0.54	20	0.02	7	0.07	3	0.46	1	0.30	4.5	0.34
Vim 2–17	+ (41%)	19	0.72	7	0.49	3.29	0.34	7	< 0.01	7	0.48	17	0.08	6	0.13	3	0.50	1	0.61	4	0.45
Vim 2–17	- (59%)	20	0.72	7	0.49	3.36	0.34	11	< 0.01	7	0.48	20	0.08	7	0.13	3	0.50	1	0.61	4	0.45
Fibα 36–50	+ (36%)	20	0.73	8	0.86	3.29	0.68	8	0.04	7	0.46	17	0.08	6	0.05	3	0.84	0.5	0.29	4	0.59
Fibα 36–50	- (64%)	19	0.73	7	0.86	3.41	0.68	11	0.04	7	0.46	19	0.08	7	0.05	3	0.84	1	0.29	4	0.59
Fibα 591	+ (32%)	19	0.70	6	0.29	3.29	0.05	7	< 0.01	6	0.28	17	0.53	6	0.88	3	0.86	1	0.33	4.5	0.70
Fibα 591	- (68%)	20	0.70	8	0.29	3.40	0.05	11	< 0.01	7	0.28	19	0.53	7	0.88	3	0.86	0.5	0.33	4	0.70
Fibβ 74	+ (30%)	22	0.19	8	0.87	3.25	0.53	9	0.12	8	0.74	17	0.08	6	0.67	2.5	0.57	0.5	0.32	4	0.48
Fibβ 74	- (70%)	18	0.19	7	0.87	3.33	0.53	10	0.12	7	0.74	19	0.08	7	0.67	3	0.57	1	0.32	4	0.48
Fibβ 72	+ (12%)	21	0.25	5	0.59	3.59	0.37	10	0.48	9	0.52	22	0.19	9	0.06	3	0.73	0.5	0.72	4	0.98
Fibβ 72	- (88%)	19	0.25	7	0.59	3.31	0.37	9	0.48	7	0.52	17	0.19	6	0.06	3	0.73	1	0.72	4	0.98

Anti-citrullinated protein antibody (ACPA) reactivities are sorted by decreasing frequency in the cohort: p values (p) were derived from the Mann-Whitney U test; statistically significant differences are in italics
Abbreviations: ESR erythrocyte sedimentation rate (millimetre/hour, 1–140), CRP C-reactive protein (milligram/litre), DAS Disease Activity Score (0–10), SJC swollen joint count (0–44), RAI Ritchie articular index (0–78), US ultrasound, GS grey scale (0–96), PD power Doppler (0–96), vdHSS van der Heijde modified Sharp score, E erosion (0–280), JSN joint space narrowing (0–168), T total (0–448), anti-CCP anti-cyclic citrullinated peptide, Fib fibrinogen, Vim vimentin, H histone, CEP-1 citrullinated enolase peptide-1, Fil filaggrin; numbers referring to amino acid sequence

Back to article page

ISSN: 1478-6362

Contact us

General enquiries: journalsubmissions@springernature.com

Arthritis Research & Therapy

Contact us